RxDoctor Payments Data

Michael Greenley, MD

Ophthalmology · Farmington Hills, MINPI 1952392813

Payments from drug & device makers

$1,301in general payments, 2019–2025

Across 69 payments — averaging $18.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$230
  • AbbVie$147
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$113
  • Sun Pharmaceutical Industries Inc.$107
  • Bausch & Lomb Americas Inc.$96
  • Alcon$91
  • plus $517 from 15 others

What the payments were for

  • Food & beverage$1,301100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,301 in reported general payments places this provider in the 50th percentile of 674 ophthalmology providers in Michigan.

See all ophthalmology providers in Michigan

Medicare billing

Part B allowed, 2024
$251,019
Medicare patients
680
Services billed
3,144

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost129$74,396
RestasisCyclosporine107$72,770
Cyclosporine76$31,501
Latanoprost715$13,595
XiidraLifitegrast19$13,094
Ketorolac Tromethamine450$11,593
CombiganBrimonidine Tartrate/Timolol14$9,575
Tobramycin-DexamethasoneTobramycin/Dexamethasone159$9,156
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol26$8,339
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat314$7,708
Bimatoprost30$4,599
Prednisolone Acetate129$3,948
Travoprost16$3,733
Brimonidine Tartrate181$3,001
Timolol Maleate131$1,820

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$147$156,741250 claims
Bausch & Lomb Americas Inc.Xiidra$96$13,09419 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 674 ophthalmology providers in Michigan.

Other ophthalmology in Farmington Hills

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →